RxDoctor Payments Data

Douglas Lanoue, MD

Family Medicine · Onarga, ILNPI 1700032646

Payments from drug & device makers

$1,407in general payments, 2019–2025

Across 82 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$307
  • AstraZeneca$210
  • Lilly USA, LLC$171
  • Radius Health, Inc.$121
  • Johnson & Johnson$78
  • Boehringer Ingelheim$77
  • plus $442 from 14 others

What the payments were for

  • Food & beverage$1,36297%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,407 in reported general payments places this provider in the 75th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$1,113
Medicare patients
11
Services billed
14

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide91$95,691
JardianceEmpagliflozin129$94,162
OzempicSemaglutide64$61,866
EliquisApixaban64$44,473
Synjardy XrEmpagliflozin/Metformin Hcl37$24,491
MyrbetriqMirabegron28$20,742
Tresiba Flextouch U-200Insulin Degludec25$19,777
FarxigaDapagliflozin Propanediol17$17,321
XareltoRivaroxaban19$12,759
Breo ElliptaFluticasone/Vilanterol29$11,574
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$6,242
Varenicline Tartrate19$6,100
Incruse ElliptaUmeclidinium Bromide17$5,981
Levemir FlexpenInsulin Detemir25$3,667
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$307$157,556155 claims
Boehringer IngelheimJardiance, Synjardy Xr$77$118,653166 claims
PfizerEliquis$49$44,47364 claims
GSKBreo Ellipta, Incruse Ellipta$32$17,55546 claims
AstraZenecaFarxiga$210$17,32117 claims
Johnson & JohnsonXarelto$78$12,75919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Onarga

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →